Bristol-Myers Squibb (BMS; NYSE: BMY) has announced that a late-stage trial for its checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) in patients with unresectable stage III non-small cell lung cancer (NSCLC) did not achieve its primary endpoint of progression-free survival (PFS). The study compared the efficacy and safety of Opdivo in combination with concurrent chemoradiotherapy (CCRT), followed by Opdivo plus Yervoy, to a regimen of CCRT followed by AstraZeneca’s (AZ; NASDAQ: AZN) anti-PD-L1 drug Imfinzi (durvalumab).
BMS plans to publish comprehensive results once a full evaluation of the trial data is completed. The company confirmed that the safety profile of the Opdivo and Yervoy combination was in line with the known profiles of each individual component.
As stated in the press release, combinations of Opdivo have received regulatory approval in certain settings for resectable or metastatic NSCLC.- Flcube.com
